Company Overview and News

Hong Kong buyers snap up a quarter of flats in ‘youth oriented’ project in Yau Tong on Friday

2018-10-13 scmp
About a quarter of the flats at a development targeted towards young and first-time buyers in Yau Tong, Kowloon were snapped up late Friday, a modest result after a tumultuous week for local asset prices amid concerns that Hong Kong will not be immune to fallout from the worsening China-US trade war.

Suddenly, there’s a tinge of fear among sellers in Hong Kong’s property market

2018-10-11 scmp
A recent wave of price discounting for both residential and commercial properties indicates a softening in sentiment
0813 SIOPF SHMAY 0034

Hard to find flats priced under HK$4m back on the market as developers court young buyers

2018-10-05 scmp
Young buyers eager to get on the property ladder can heave a sigh of relief as more flats priced under HK$4 million (US$510,341) are coming on the market.
STAN 580001 STAB STAN STAC 2888 SCBFF 0034

As homebuyers wait on the sidelines, builders tempt them with special mortgage rates, cash discounts

2018-10-04 scmp
The incentives come after residential property transactions in Hong Kong fall to a 20-month low in September

Taller, higher-density towers are the answer to Hong Kong’s property crisis, say developers and industry groups

2018-09-26 scmp
But the answer to the chronic shortage of housing and commercial property in Hong Kong may be taller buildings of even higher density, according to developers and industry groups.
1972 SWROY SWPFF 0034

How small can Hong Kong’s apartments be? This builder is aiming for a record at 123 sq ft

2018-04-19 scmp
Hong Kong’s developers are shrinking their apartments, as surging prices severely limit the amount of money that first-time buyers and school-leavers can put down on their property, putting all but the smallest units beyond their budgets.

One in four Hongkongers can’t ever afford a home, as a micro flat sells for another record price

2018-03-20 scmp
A 209 sq ft unit was sold for HK$37,651 per square foot, setting a record for the micro-apartments in the city.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...